Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms GOLILOR
- 26 Nov 2018 Planned End Date changed from 31 Jan 2019 to 30 May 2020.
- 26 Nov 2018 Planned primary completion date changed from 31 Aug 2018 to 30 Oct 2019.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.